Niyas Abdullah Mohamed, Haseefa Fathima, Cox Jordy Charles, Movahed Mohammad Reza
University of Arizona College of Medicine Phoenix, AZ, USA.
Creighton University Phoenix, AZ, USA.
Am J Cardiovasc Dis. 2024 Apr 15;14(2):116-120. doi: 10.62347/FXLN8938. eCollection 2024.
Colchicine is one of the established drugs of choice for post-myocardial infarction (MI) induced pericarditis, given its anti-inflammatory properties. Recently, colchicine received FDA approval for secondary prevention of atherosclerotic cardiovascular disease, which leads to concerns regarding its anti-healing effects on myocardial tissue post-infarction. We present a case of a suspected colchicine-induced myocardial rupture in an elderly male, who presented with a syncopal episode while on colchicine three weeks after the late presentation of infero-posterior ST-elevation myocardial infarction.
秋水仙碱因其抗炎特性，是心肌梗死（MI）后诱发心包炎的既定首选药物之一。最近，秋水仙碱获得了美国食品药品监督管理局（FDA）对动脉粥样硬化性心血管疾病二级预防的批准，这引发了人们对其对心肌梗死后心肌组织抗愈合作用的担忧。我们报告一例老年男性疑似秋水仙碱诱发心肌破裂的病例，该患者在出现下后壁ST段抬高型心肌梗死后三周，服用秋水仙碱期间出现晕厥发作。
